|
3189
|
4-CPPC
|
First potent, selective and reversible inhibitor of MIF-2 |
€135.00 |
|
3108
|
BC-LI-0186
|
Specific inhibitor of the LRS-RagD interaction |
€90.00 |
|
3238
|
Cytarabine
|
Inhibitor of DNA synthesis; Antimetabolite |
€50.00 |
|
3200
|
DCLK1-IN-1
|
Potent, selective and orally bioavailable DCLK1/2 inhibitor |
€140.00 |
|
3326
|
HJC0197
|
Potent EPAC antagonist |
€90.00 |
|
3202
|
LEI-401
|
First-in-class, potent, selective and CNS-active NAPE-PLD inhibitor |
€190.00 |
|
3165
|
Lenvatinib
|
Multi-targeted receptor tyrosine kinase inhibitor |
€70.00 |
|
3270
|
Lj-1-60
|
Fyn inhibitor targeting the Fyn/Stat3 pathway |
€90.00 |
|
3234
|
Lumacaftor
|
Selective and orally bioavailable CFTR corrector |
€70.00 |
|
3236
|
Montelukast sodium
|
Potent and selective CysLT1 receptor antagonist |
€70.00 |
|
3105
|
Olmesartan
|
Potent and selective AT1 antagonist |
€80.00 |
|
3162
|
Pemetrexed disodium
|
Inhibitor of DHFR/TS/GARFT; Antifolate antimetabolite |
€50.00 |
|
3255
|
Pioglitazone hydrochloride
|
PPARγ agonist; antidiabetic drug |
€50.00 |
|
3215
|
RIG012
|
Potent antagonist of the RIG-I innate immune receptor |
€150.00 |
|
3175
|
Rivaroxaban
|
Highly potent, selective and oral direct FXa inhibitor |
€70.00 |